Autoimmune Disease Diagnostics Market Forecasts to 2028 – Global Analysis By Disease Type (Localized Autoimmune Disease, Systemic Autoimmune Disease), Test Type (C-reactive Protein (CRP) Test, Antinuclear Antibody Test, Complete Blood Count (CBC), Urinalysis, Erythrocyte Sedimentation Rate (ESR), Comprehensive Metabolic Panel, Biopsy) and Others
According tStratistics MRC, the Global Autoimmune Disease Diagnostics Market is accounted for $1198.9 billion in 2022 and is expected treach $1966.8 billion by 2028 growing at a CAGR of 8.6% during the forecast period. An autoimmune illness is a condition brought on by an unexpected immune reaction ta healthy bodily part. It is a condition that is typically brought on by either moderate or excessive immune system activity. In these situations, the immune system attacks and damages its own tissue, weakening the body's ability tfight against infections and internal organ failure. Systematic autoimmune illness and localised autoimmune disease are the twmost common forms of autoimmune diseases.
According tthe CDC National Diabetes Statistics Report, 2020, around 1.4 million people in the U.S. suffer from Type-1 diabetes. This number is estimated tincrease t2.1 million by 2040.
Market Dynamics:
Driver:
Increased Awareness Regarding the Autoimmune Diseases
One of the main causes of autoimmune illnesses is stress. Other prominent causes include genetic alterations, poor dietary habits, and environmental variables. The requirement for autoimmune disease diagnostics is increased by the growing prevalence of autoimmune disorders around the world. The initiatives performed by numerous governmental and private organisations are alsresponsible for a rise in public knowledge concerning the diagnosis and treatment of autoimmune disorders. The autoimmune disease diagnostics industry is growing as a result of the importance of early diagnosis in lowering morbidity, mortality, and disability among people.
Restraint:
High cost of diagnostic tests
A significant obstacle tthe expansion of the market for diagnosing autoimmune diseases is the massive price of diagnostic tests. According tresearch conducted by the National Adrenal Disorders Foundation (NADF), Addison's disease initial diagnosis costs $1,680 per patient. The Vasculitis Foundation of America says that 1 in 20 Americans have vasculitis, which has a total annual cost of $9.7 billion. The market for diagnosing autoimmune diseases is growing, but the exorbitant expense of diagnostics is putting people under greater financial strain.
Opportunity:
New Product Launches for Autoimmune Disease Diagnostics
Many tests are used tidentify autoimmune diseases, and in some cases, they can alshelp assess how severe the condition is. In addition tdetermining the nature of the patient's problem, the right autoimmune blood test may demonstrate tpatients their necessary treatment plan or lifestyle changes. The higher incidence of autoimmune disorders is increasing public awareness of the diagnosis of these illnesses. These elements are expected tfuel the market for testing autoimmune diseases during the anticipated time frame.
Threat:
Lack of Penetration of these Products in Developing Region
The prevalence of autoimmune disorders such Inflammatory Bowel Disease (IBD), rheumatoid arthritis, and others is increasing, which is fuelling market growth. The market penetration of important products is being constrained in numerous emerging nations due tthe restricted availability of epidemiological data, lack of access teffective diagnostic techniques, and a shortage of qualified healthcare personnel. The frequency of initial and pursue consultations for these patients is alsbeing constrained by the general public's ignorance of these disorders. In the projection period, this is anticipated thinder the market's ability tgrow more significantly.
Covid-19 Impact
In several nations, the COVID-19 epidemic caused a public health emergency that resulted in widespread lockdowns and restrictions. The majority of the healthcare services and resources were devoted tCOVID-19 as a top priority. Similar tthis, laboratory staff and resources were focused on containing the COVID-19 epidemic. The hospitals alsexperienced a significant influx of COVID-19 patients, utilising their resources for testing and treating the sick people. As a result, many unnecessary, non-urgent, or elective operations and appointments—including the disease diagnosis of autoimmune diseases—were cancelled, put off, or postponed, which had a detrimental effect on the adoption of tests. The rigorous lockdowns and limitations disrupted the supply chain, which caused delays in the delivery of the lab supplies and equipment. These restrictions limited the market's ability texpand in some ways, but as rapid diagnostic services improve, the market is starting tgain momentum.
The Systemic Autoimmune Diseases segment is expected tbe the largest during the forecast period
The Systemic Autoimmune Diseases segment is estimated thave a lucrative growth. Different from localised autoimmune disorders, which only affect a specific organ or area of the body, systemic autoimmune diseases impact several organs or systems. Rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus are three of the most prevalent autoimmune illnesses that are systemic in origin (SLE). Thus, one of the main reasons for the big proportion of the category is the higher incidence of systemic autoimmune illnesses.
The hospital segment is expected thave the highest CAGR during the forecast period
The hospital segment is anticipated twitness the fastest CAGR growth during the forecast period; due tincrease of diagnostic capabilities across all hospitals and patient volume preferences for the hospitals which now provide comprehensive care including diagnostics, operations or treatments, and physiotherapy are the main drivers causing this largest segment share. In order toffer quick and affordable tests tthe general public, hospitals are expanding their use of already available technologies and adopting new ones at a rapid rate.
Region with highest share:
Asia Pacific is projected thold the largest market share during the forecast period owing trising disposable income and a sizable patient population in emerging economies. Infrastructure development and the increased need for precise diagnosis are further significant drivers. Future growth of this proportion is more likely, and increased autoimmune disease prevalence will boost market revenue. Asia-Pacific is therefore anticipated texperience the fastest growth rate during the forecast period for the market for autoimmunity disease diagnosis. Also, the Indian autoimmune disease part of the business was the one with the quickest growth in Asia-Pacific, while the Chinese autoimmune disease diagnostics market had the greatest market share.
Region with highest CAGR:
Europe is projected thave the highest CAGR over the forecast period, owing tincrease in the elderly population and the frequency of autoimmune diseases among the elderly are the twreasons driving the market's growth. Moreover, rising chronic disease burden and public awareness will fuel market expansion. There are more product releases and more collaboration amongst the major market players as a way taccelerate market expansion in Europe.
Key players in the market
Some of the key players profiled in the Autoimmune Disease Diagnostics Market include Myriad Genetics, Beutner , Siemens Healthineers Inc., Abbott Laboratories, Trinity Biotech, ThermFisher Scientific, Inova Diagnostics Inc., Danaher Corp., F. Hoffmann-La Roche Ltd., Quest Diagnostics Inc., Hemagen Diagnostics, Inc., Nova Diagnostics and Beckman Coulter.
Key Developments:
In August 2022, Beutner announced that it had introduced a new blood test tidentify an antigen for autoimmune blistering diseasemucous membrane pemphigoid, which causes discomfort in the oral cavity of the patient.
In May 2022, ThermFisher Scientific (United States) has launched new instruments under Phadia 2500+ series. These instruments are used for autoimmune testing and offer unparalleled and consistently high throughput for autoimmune testing and allergy diagnostics.
In February 2021, Myriad Genetics has launched its new novel enhancement globally on its Vecta test report. This test report is used tidentify any individual estimate of a patient's risk over a period of one year for rapid radiographic progression (RP). The new test report provides personalized RP results based on the gender, age and adiposity of a patient.
Diseases Types Covered:
• Localized Autoimmune Disease
• Systemic Autoimmune Disease
Test Types Covered:
• C-reactive Protein (CRP) Test
• Antinuclear Antibody Test
• Complete Blood Count (CBC)
• Urinalysis
• Erythrocyte Sedimentation Rate (ESR)
• Comprehensive Metabolic Panel
• Autoantibody Test
• Imaging Test
• Biopsy
• Other Test Types
Factors Covered:
• Environmental Agents
• Diet
• Genetics
Products Covered:
• Instruments
• Kits and Assays
• Reagents
• Consumables
Treatment Types Covered:
• Physical Therapy
• Nonsteroidal Anti-Inflammatory Drugs
• Plasma Exchange
• Immune-Suppressing Drugs
• Blood Transfusion
• Hormone Replacement Therapy
• Other Treatment Types
End Users Covered:
• Diagnostic Laboratories
• Hospital
• Clinics
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Autoimmune Disease Diagnostics Market, By Disease Type
- 5.1 Introduction
- 5.2 Localized Autoimmune Disease
- 5.2.1 Type 1 Diabetes
- 5.2.2 Inflammatory Bowel Disease
- 5.2.3 Thyroid
- 5.2.4 Other Localized Autoimmune Diseases
- 5.3 Systemic Autoimmune Disease
- 5.3.1 Multiple Sclerosis
- 5.3.2 Rheumatoid Arthritis
- 5.3.3 Systemic Lupus Erythematosus (SLE)
- 5.3.4 Psoriasis
- 5.3.5 Graves' Disease
- 5.3.6 Other Systemic Autoimmune Diseases
- 6 Global Autoimmune Disease Diagnostics Market, By Test Type
- 6.1 Introduction
- 6.2 C-reactive Protein (CRP) Test
- 6.3 Antinuclear Antibody Test
- 6.4 Complete Blood Count (CBC)
- 6.5 Urinalysis
- 6.6 Erythrocyte Sedimentation Rate (ESR)
- 6.7 Comprehensive Metabolic Panel
- 6.8 Autoantibody Test
- 6.9 Imaging Test
- 6.10 Biopsy
- 6.11 Other Test Types
- 7 Global Autoimmune Disease Diagnostics Market, By Factors
- 7.1 Introduction
- 7.2 Environmental Agents
- 7.3 Diet
- 7.4 Genetics
- 8 Global Autoimmune Disease Diagnostics Market, By Product
- 8.1 Introduction
- 8.2 Instruments
- 8.3 Kits and Assays
- 8.4 Reagents
- 8.5 Consumables
- 9 Global Autoimmune Disease Diagnostics Market, By Treatment Type
- 9.1 Introduction
- 9.2 Physical Therapy
- 9.3 Nonsteroidal Anti-Inflammatory Drugs
- 9.4 Plasma Exchange
- 9.5 Immune-Suppressing Drugs
- 9.6 Blood Transfusion
- 9.7 Hormone Replacement Therapy
- 9.8 Other Treatment Types
- 10 Global Autoimmune Disease Diagnostics Market, By End User
- 10.1 Introduction
- 10.2 Diagnostic Laboratories
- 10.3 Hospital
- 10.4 Clinics
- 10.5 Other End Users
- 11 Global Autoimmune Disease Diagnostics Market, By Geography
- 11.1 Introduction
- 11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
- 11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa
- 12 Key Developments
- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies
- 13 Company Profiling
- 13.1 Myriad Genetics
- 13.2 Beutner
- 13.3 Siemens Healthineers Inc.
- 13.4 Abbott Laboratories
- 13.5 Trinity Biotech
- 13.6 Thermo Fisher Scientific
- 13.7 Inova Diagnostics Inc.
- 13.8 Danaher Corp.
- 13.9 F. Hoffmann-La Roche Ltd.
- 13.10 Quest Diagnostics Inc.
- 13.11 Hemagen Diagnostics, Inc.
- 13.12 Nova Diagnostics
- 13.13 Beckman Coulter
- List of Tables
- Table 1 Global Autoimmune Disease Diagnostics Market Outlook, By Region (2020-2028) ($MN)
- Table 2 Global Autoimmune Disease Diagnostics Market Outlook, By Disease Type (2020-2028) ($MN)
- Table 3 Global Autoimmune Disease Diagnostics Market Outlook, By Localized Autoimmune Disease (2020-2028) ($MN)
- Table 4 Global Autoimmune Disease Diagnostics Market Outlook, By Type 1 Diabetes (2020-2028) ($MN)
- Table 5 Global Autoimmune Disease Diagnostics Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
- Table 6 Global Autoimmune Disease Diagnostics Market Outlook, By Thyroid (2020-2028) ($MN)
- Table 7 Global Autoimmune Disease Diagnostics Market Outlook, By Other Localized Autoimmune Diseases (2020-2028) ($MN)
- Table 8 Global Autoimmune Disease Diagnostics Market Outlook, By Systemic Autoimmune Disease (2020-2028) ($MN)
- Table 9 Global Autoimmune Disease Diagnostics Market Outlook, By Multiple Sclerosis (2020-2028) ($MN)
- Table 10 Global Autoimmune Disease Diagnostics Market Outlook, By Rheumatoid Arthritis (2020-2028) ($MN)
- Table 11 Global Autoimmune Disease Diagnostics Market Outlook, By Systemic Lupus Erythematosus (SLE) (2020-2028) ($MN)
- Table 12 Global Autoimmune Disease Diagnostics Market Outlook, By Psoriasis (2020-2028) ($MN)
- Table 13 Global Autoimmune Disease Diagnostics Market Outlook, By Graves' Disease (2020-2028) ($MN)
- Table 14 Global Autoimmune Disease Diagnostics Market Outlook, By Other Systemic Autoimmune Diseases (2020-2028) ($MN)
- Table 15 Global Autoimmune Disease Diagnostics Market Outlook, By Test Type (2020-2028) ($MN)
- Table 16 Global Autoimmune Disease Diagnostics Market Outlook, By C-reactive Protein (CRP) Test (2020-2028) ($MN)
- Table 17 Global Autoimmune Disease Diagnostics Market Outlook, By Antinuclear Antibody Test (2020-2028) ($MN)
- Table 18 Global Autoimmune Disease Diagnostics Market Outlook, By Complete Blood Count (CBC) (2020-2028) ($MN)
- Table 19 Global Autoimmune Disease Diagnostics Market Outlook, By Urinalysis (2020-2028) ($MN)
- Table 20 Global Autoimmune Disease Diagnostics Market Outlook, By Erythrocyte Sedimentation Rate (ESR) (2020-2028) ($MN)
- Table 21 Global Autoimmune Disease Diagnostics Market Outlook, By Comprehensive Metabolic Panel (2020-2028) ($MN)
- Table 22 Global Autoimmune Disease Diagnostics Market Outlook, By Autoantibody Test (2020-2028) ($MN)
- Table 23 Global Autoimmune Disease Diagnostics Market Outlook, By Imaging Test (2020-2028) ($MN)
- Table 24 Global Autoimmune Disease Diagnostics Market Outlook, By Biopsy (2020-2028) ($MN)
- Table 25 Global Autoimmune Disease Diagnostics Market Outlook, By Other Test Types (2020-2028) ($MN)
- Table 26 Global Autoimmune Disease Diagnostics Market Outlook, By Factors (2020-2028) ($MN)
- Table 27 Global Autoimmune Disease Diagnostics Market Outlook, By Environmental Agents (2020-2028) ($MN)
- Table 28 Global Autoimmune Disease Diagnostics Market Outlook, By Diet (2020-2028) ($MN)
- Table 29 Global Autoimmune Disease Diagnostics Market Outlook, By Genetics (2020-2028) ($MN)
- Table 30 Global Autoimmune Disease Diagnostics Market Outlook, By Product (2020-2028) ($MN)
- Table 31 Global Autoimmune Disease Diagnostics Market Outlook, By Instruments (2020-2028) ($MN)
- Table 32 Global Autoimmune Disease Diagnostics Market Outlook, By Kits and Assays (2020-2028) ($MN)
- Table 33 Global Autoimmune Disease Diagnostics Market Outlook, By Reagents (2020-2028) ($MN)
- Table 34 Global Autoimmune Disease Diagnostics Market Outlook, By Consumables (2020-2028) ($MN)
- Table 35 Global Autoimmune Disease Diagnostics Market Outlook, By Treatment Type (2020-2028) ($MN)
- Table 36 Global Autoimmune Disease Diagnostics Market Outlook, By Physical Therapy (2020-2028) ($MN)
- Table 37 Global Autoimmune Disease Diagnostics Market Outlook, By Nonsteroidal Anti-Inflammatory Drugs (2020-2028) ($MN)
- Table 38 Global Autoimmune Disease Diagnostics Market Outlook, By Plasma Exchange (2020-2028) ($MN)
- Table 39 Global Autoimmune Disease Diagnostics Market Outlook, By Immune-Suppressing Drugs (2020-2028) ($MN)
- Table 40 Global Autoimmune Disease Diagnostics Market Outlook, By Blood Transfusion (2020-2028) ($MN)
- Table 41 Global Autoimmune Disease Diagnostics Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
- Table 42 Global Autoimmune Disease Diagnostics Market Outlook, By Other Treatment Types (2020-2028) ($MN)
- Table 43 Global Autoimmune Disease Diagnostics Market Outlook, By End User (2020-2028) ($MN)
- Table 44 Global Autoimmune Disease Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
- Table 45 Global Autoimmune Disease Diagnostics Market Outlook, By Hospital (2020-2028) ($MN)
- Table 46 Global Autoimmune Disease Diagnostics Market Outlook, By Clinics (2020-2028) ($MN)
- Table 47 Global Autoimmune Disease Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
- Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook